- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | ABVC BIOPHARMA, INC. - 8-K, Current Report | - | SEC Filings | ||
| 22.10. | ABVC BioPharma sichert sich zusätzliche Lizenzgebühren | 3 | Investing.com Deutsch | ||
| 22.10. | ABVC BioPharma, Inc.: ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners | 41 | GlobeNewswire (Europe) | FREMONT, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous... ► Artikel lesen | |
| 22.10. | ABVC BioPharma secures additional licensing fees | 1 | Investing.com | ||
| 19.10. | ABVC BioPharma switches to new independent accounting firm | 1 | Investing.com | ||
| 19.10. | ABVC BioPharma wechselt zu neuer unabhängiger Wirtschaftsprüfungsgesellschaft | 1 | Investing.com Deutsch | ||
| 18.10. | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.09. | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.08. | ABVC BioPharma GAAP EPS of -$0.09 | 1 | Seeking Alpha | ||
| 15.08. | ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements | 136 | GlobeNewswire (Europe) | • Executed Global Licensing Agreements that could provide up to $292 million in income • Received Cash Milestone Incomes of $116,000 • Achieved Significant Improvements in Earnings • Obtained... ► Artikel lesen | |
| 15.08. | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.08. | ABVC BIOPHARMA, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 23.07. | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.07. | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.06. | ABVC Biopharma files to sell 1M shares of common stock for holders | 1 | Seeking Alpha | ||
| 21.06. | ABVC BIOPHARMA, INC. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 23.05. | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.05. | ABVC BIOPHARMA, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.05. | ABVC BIOPHARMA, INC. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 2 | SEC Filings | ||
| 09.05. | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,695 | -1,45 % | EQS-DD: NanoRepro AG: Dr. Olaf Stiller, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
29.10.2024 / 12:15... ► Artikel lesen | |
| BIOXXMED | 2,730 | -4,55 % | EQS-Adhoc: bioXXmed AG: Platzierung der Kapitalerhöhung abgeschlossen | EQS-Ad-hoc: bioXXmed AG / Schlagwort(e): Sonstiges
bioXXmed AG: Platzierung der Kapitalerhöhung abgeschlossen
01.10.2024 / 17:12 CET/CEST
Veröffentlichung einer Insiderinformation nach Artikel... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,048 | +14,46 % | Sirona Biochem Aktie: Zeichen der Schwäche | Die Sirona Biochem Aktie zeigt sich derzeit in einer herausfordernden Position. Mit einem aktuellen Kurs von 0,0415 EUR (Stand: 26. Oktober) verzeichnet das Unternehmen einen monatlichen Rückgang von... ► Artikel lesen | |
| TREVENA | 0,153 | 0,00 % | Trevena, Inc.: Trevena Announces Receipt of Nasdaq Delisting Notification | CHESTERBROOK, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with... ► Artikel lesen | |
| REDHILL BIOPHARMA | 7,910 | 0,00 % | RedHill Biopharma Ltd.: New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality | Data, from a post hoc analysis of the randomized, placebo-controlled, double-blind phase 2/3 study of oral opaganib in COVID-19 pneumonia, showing a 62% reduction in mortality and a 21% improvement... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,600 | +1,73 % | BioXcel Therapeutics Aktie: Kursanstieg trotz Monatsverlust | BioXcel Therapeutics verzeichnete am 15. Oktober 2024 einen leichten Kursanstieg von 0,92% auf 0,4981 EUR. Trotz dieses Tagesgewinns bleibt die Aktie des biopharmazeutischen Unternehmens auf Monatssicht... ► Artikel lesen | |
| CELLECTIS | 1,694 | +0,83 % | Cellectis Provides Business Updates and Financial Results for Third Quarter 2024 | UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in 2025AstraZeneca partnership: R&D activities are ongoing on three programs - one allogeneic... ► Artikel lesen | |
| SPERO THERAPEUTICS | 1,170 | -1,35 % | Spero shares hold Buy rating with target lowered on SPR720 Phase 2a results | ||
| BIORA THERAPEUTICS | 3,060 | -9,33 % | Aktie von Progenity Inc erreicht 52-Wochen-Tief bei 3,38 US-Dollar | ||
| ADICET BIO | 1,137 | -2,32 % | Adicet Bio, Inc.: Adicet Bio to Participate in Upcoming Investor Conferences | Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that... ► Artikel lesen | |
| ALTERITY THERAPEUTICS | 0,001 | 0,00 % | ALTERITY THERAPEUTICS LIMITED: Appendix 4C - Q1 FY25 Quarterly Cash Flow Report | Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for release in January 2025Positive interim data reported from ATH434-202 Phase 2 clinical trial showing... ► Artikel lesen | |
| WINDTREE THERAPEUTICS | 0,700 | 0,00 % | Windtree Therapeutics: Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock | Istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrythmias NYHA heart failure... ► Artikel lesen | |
| DURECT | 1,240 | 0,00 % | DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis | - Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design
- Single Phase 3 trial designed to enroll 200 U.S. patients with a... ► Artikel lesen | |
| ALTAMIRA THERAPEUTICS | 0,481 | 0,00 % | Altamira Therapeutics Ltd: Altamira Therapeutics Provides Update on Nasdaq Listing | Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the... ► Artikel lesen | |
| SERES THERAPEUTICS | 0,754 | +2,53 % | Führungskraft von Seres Therapeutics verkauft Aktien im Wert von 2.749 US-Dollar |
ABVC BIOPHARMA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,660 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABVC BIOPHARMA INC finden Sie auf Wallstreet Online.
